Alexander Hermann1, Katharina Riss1, Peter Schellongowski1, Andja Bojic1, Philipp Wohlfarth1, Oliver Robak1, Wolfgang R Sperr1, Thomas Staudinger2. 1. Department of Medicine I, Intensive Care Unit 13i2, General Hospital Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. 2. Department of Medicine I, Intensive Care Unit 13i2, General Hospital Vienna, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. thomas.staudinger@meduniwien.ac.at.
Abstract
PURPOSE: Pump-driven veno-venous extracorporeal CO2-removal (ECCO2-R) increasingly takes root in hypercapnic lung failure to minimize ventilation invasiveness or to avoid intubation. A recently developed device (iLA activve(®), Novalung, Germany) allows effective decarboxylation via a 22 French double lumen cannula. To assess determinants of gas exchange, we prospectively evaluated the performance of ECCO2-R in ten patients receiving iLA activve(®) due to hypercapnic respiratory failure. METHODS: Sweep gas flow was increased in steps from 1 to 14 L/min at constant blood flow (phase 1). Similarly, blood flow was gradually increased at constant sweep gas flow (phase 2). At each step gas transfer via the membrane as well as arterial blood gas samples were analyzed. RESULTS: During phase 1, we observed a significant increase in CO2 transfer together with a decrease in PaCO2 levels from a median of 66 mmHg (range 46-85) to 49 (31-65) mmHg from 1 to 14 L/min sweep gas flow (p < 0.0001), while arterial oxygenation deteriorated with high sweep gas flow rates. During phase 2, oxygen transfer significantly increased leading to an increase in PaO2 from 67 (49-87) at 0.5 L/min to 117 (66-305) mmHg at 2.0 L/min (p < 0.0001). Higher blood flows also significantly enhanced decarboxylation (p < 0.0001). CONCLUSIONS: Increasing sweep gas flow results in effective CO2-removal, which can be further reinforced by raising blood flow. The clinically relevant oxygenation effect in this setting could broaden the range of indications of the system and help to set up an individually tailored configuration.
PURPOSE: Pump-driven veno-venous extracorporeal CO2-removal (ECCO2-R) increasingly takes root in hypercapnic lung failure to minimize ventilation invasiveness or to avoid intubation. A recently developed device (iLA activve(®), Novalung, Germany) allows effective decarboxylation via a 22 French double lumen cannula. To assess determinants of gas exchange, we prospectively evaluated the performance of ECCO2-R in ten patients receiving iLA activve(®) due to hypercapnic respiratory failure. METHODS: Sweep gas flow was increased in steps from 1 to 14 L/min at constant blood flow (phase 1). Similarly, blood flow was gradually increased at constant sweep gas flow (phase 2). At each step gas transfer via the membrane as well as arterial blood gas samples were analyzed. RESULTS: During phase 1, we observed a significant increase in CO2 transfer together with a decrease in PaCO2 levels from a median of 66 mmHg (range 46-85) to 49 (31-65) mmHg from 1 to 14 L/min sweep gas flow (p < 0.0001), while arterial oxygenation deteriorated with high sweep gas flow rates. During phase 2, oxygen transfer significantly increased leading to an increase in PaO2 from 67 (49-87) at 0.5 L/min to 117 (66-305) mmHg at 2.0 L/min (p < 0.0001). Higher blood flows also significantly enhanced decarboxylation (p < 0.0001). CONCLUSIONS: Increasing sweep gas flow results in effective CO2-removal, which can be further reinforced by raising blood flow. The clinically relevant oxygenation effect in this setting could broaden the range of indications of the system and help to set up an individually tailored configuration.
Entities:
Keywords:
Decarboxylation; ECCO2-R; Extracorporeal circulation; Hypercapnia; iLA activve®
Authors: Xiaoqin Zhou; David B Loran; Dongfang Wang; Brannon R Hyde; Scott D Lick; Joseph B Zwischenberger Journal: Perfusion Date: 2005-10 Impact factor: 1.972
Authors: Peter Schellongowski; Katharina Riss; Thomas Staudinger; Roman Ullrich; Claus G Krenn; Christian Sitzwohl; Andja Bojic; Philipp Wohlfarth; Wolfgang R Sperr; Werner Rabitsch; Clemens Aigner; Shahrokh Taghavi; Peter Jaksch; Walter Klepetko; György Lang Journal: Transpl Int Date: 2014-12-05 Impact factor: 3.782
Authors: Peter D Wearden; William J Federspiel; Scott W Morley; Meir Rosenberg; Paul D Bieniek; Laura W Lund; Burt D Ochs Journal: Intensive Care Med Date: 2012-08-25 Impact factor: 17.440
Authors: T Müller; M Lubnow; A Philipp; T Bein; A Jeron; A Luchner; L Rupprecht; M Reng; J Langgartner; C E Wrede; M Zimmermann; D Birnbaum; C Schmid; G A J Riegger; M Pfeifer Journal: Eur Respir J Date: 2008-11-14 Impact factor: 16.671
Authors: Thomas Bein; Steffen Weber-Carstens; Anton Goldmann; Thomas Müller; Thomas Staudinger; Jörg Brederlau; Ralf Muellenbach; Rolf Dembinski; Bernhard M Graf; Marlene Wewalka; Alois Philipp; Klaus-Dieter Wernecke; Matthias Lubnow; Arthur S Slutsky Journal: Intensive Care Med Date: 2013-01-10 Impact factor: 17.440
Authors: Andrea Morelli; Lorenzo Del Sorbo; Antonio Pesenti; V Marco Ranieri; Eddy Fan Journal: Intensive Care Med Date: 2017-01-28 Impact factor: 17.440
Authors: Stephan Braune; Annekatrin Sieweke; Franz Brettner; Thomas Staudinger; Michael Joannidis; Serge Verbrugge; Daniel Frings; Axel Nierhaus; Karl Wegscheider; Stefan Kluge Journal: Intensive Care Med Date: 2016-07-25 Impact factor: 17.440
Authors: Christian Karagiannidis; Stephan Strassmann; Daniel Brodie; Philine Ritter; Anders Larsson; Ralf Borchardt; Wolfram Windisch Journal: Intensive Care Med Exp Date: 2017-08-01